Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled for the third quarter of 2002.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.
Front Oncol
March 2024
Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Background: Nausea and vomiting are common side effects of Trastuzumab Deruxtecan (T-DXd), but guidelines for optimal management were not initially available. This retrospective single-center study aimed at evaluating the efficacy of two antiemetic regimens in patients receiving T-DXd.
Methods: Data from metastatic breast cancer patients receiving T-DXd were collected.
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Cancer Med
August 2023
Interdisciplinary Cancer Course Department, Gustave Roussy Cancer Center, Villejuif, France.
Introduction: Non-inferiority of NEPA (fixed combination of NK receptor antagonist (RA), netupitant, and 5-HT RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide (AC) and non-AC moderately emetogenic chemotherapy (MEC). In the MEC group a numerically higher complete response (CR: no emesis, no rescue) rate was seen for NEPA during the overall 0-120 h phase (NEPA 76.1% vs.
View Article and Find Full Text PDFDexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.
J Geriatr Oncol
July 2023
Cancer Center, Clinique de Genolier, Genolier, Switzerland.
Introduction: We recently demonstrated the non-inferiority of two dexamethasone (DEX)-sparing regimens with an oral fixed-combination of netupitant and palonosetron (NEPA) versus the guideline-recommended DEX use for cisplatin-induced nausea and vomiting. Since prevention of chemotherapy-induced nausea and vomiting is critical in older patients, we retrospectively evaluated the efficacy of the DEX-sparing regimens in this subset.
Materials And Methods: Chemo-naive patients aged >65 years treated with high-dose cisplatin (≥70 mg/m) were eligible.
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Adv Ther
July 2023
Helsinn Therapeutics (U.S.), Inc., 200 Wood Avenue South, Suite 100, Iselin, NJ, 08830, USA.
Introduction: Chemotherapy-induced nausea and vomiting (CINV) is a recognized adverse outcome among patients with cancer. This retrospective study aimed to quantify the treatment outcomes, resource utilization, and costs associated with antiemetic use to prevent CINV in a broad US population who received cisplatin-based chemotherapy.
Methods: Data from the STATinMED RWD Insights Database was collected from January 1, 2015 to December 31, 2020.
A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
J Oncol Pharm Pract
March 2024
Oregon Health & Science University, Portland, OR, USA.
The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients receiving BEAM therapy. This phase II, prospective, intention-to-treat, single-center, single-arm study involved 43 adult patients who received NEPA and dexamethasone for the prevention of CINV due to BEAM conditioning chemotherapy. An interim analysis, performed after 13 patients, determined utility versus futility, and supported continuation to full enrollment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!